Gerburg M. Wulf
Experienced in Virilizing Ovarian Tumor

Dr. Gerburg M. Wulf

Internal Medicine
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
On Staff At
Offers Telehealth
Experienced in Virilizing Ovarian Tumor
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gerburg Wulf is an Internal Medicine provider in Boston, Massachusetts. Dr. Wulf is rated as an Experienced provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Triple-Negative Breast Cancer, and Hormone Replacement Therapy (HRT).

Her clinical research consists of co-authoring 74 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Westfalische Wilhelms-Universitat
Residency
Ruprecht-Karls University
Specialties
Internal Medicine
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine
Fellowships
Beth Israel Deaconess Medical Center
Hospital Affiliations
Beth Israel Deaconess Medical Center
Languages Spoken
English
German
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, Boston, MA 02215
Call: 617-667-2100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors
Phase 1 Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: SGN-STNV
Study Phase: Phase 1
A Phase 1b Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer
A Phase 1b Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: T-DM1, Pembrolizumab
Study Phase: Phase 1
A Randomized Phase II Study Of Eribulin Mesylate With Or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
A Randomized Phase II Study Of Eribulin Mesylate With Or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Completed
Publish Date: March 06, 2024
Intervention Type: Drug
Study Drugs: Eribulin Mesylate, Pembrolizumab
Study Phase: Phase 2
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
A Phase 2 Study of Copanlisib (BAY 80-6946) in Combination With Fulvestrant in Patients With Metastatic Breast Cancer Progressing After Aromatase Inhibitor Plus CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Copanlisib, Fulvestrant
Study Phase: Phase 1/Phase 2
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3368715 in Participants With Solid Tumors and DLBCL
Enrollment Status: Terminated
Publish Date: May 20, 2022
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 10, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

74 Total Publications

Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer.
Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER⁺ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer.
Journal: medRxiv : the preprint server for health sciences
Published: September 26, 2025
View All 74 Publications
Similar Doctors
Meghan E. Shea
Distinguished in Virilizing Ovarian Tumor
Dr. Meghan E. Shea
Internal Medicine | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Meghan E. Shea
Internal Medicine | Oncology

Beth Israel Deaconess Medical Center - Hematology/Oncology

330 Brookline Avenue, Shapiro 9, 
Boston, MA 
 (0.1 miles away)
617-667-2100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Meghan Shea is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Shea is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Endometrial Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Small Cell Lung Cancer (SCLC).

Distinguished in Virilizing Ovarian Tumor
Dr. Panagiotis Fidias
Internal Medicine
Distinguished in Virilizing Ovarian Tumor
Dr. Panagiotis Fidias
Internal Medicine

Beth Israel Deaconess Medical Center - Hematology/Oncology

330 Brookline Avenue, Shapiro 9, 
Boston, MA 
 (0.1 miles away)
617-667-2100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Panagiotis Fidias is an Internal Medicine provider in Boston, Massachusetts. Dr. Fidias is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Colorectal Cancer.

Nadine M. Tung
Advanced in Virilizing Ovarian Tumor
Dr. Nadine M. Tung
Internal Medicine | Oncology
Advanced in Virilizing Ovarian Tumor
Dr. Nadine M. Tung
Internal Medicine | Oncology

Beth Israel Deaconess Medical Center - Hematology/Oncology

330 Brookline Avenue, Shapiro 9, 
Boston, MA 
 (0.1 miles away)
617-667-2100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nadine Tung is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Tung is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Breast Cancer, Ovarian Cancer, BRCA Positive Breast Cancer, Salpingo-Oophorectomy, and Hormone Replacement Therapy (HRT).

VIEW MORE VIRILIZING OVARIAN TUMOR DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wulf's expertise for a condition
ConditionClose
  • Elite
  • Breast Cancer
    Dr. Wulf is
    Elite
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Distinguished
  • Angiosarcoma
    Dr. Wulf is
    Distinguished
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • Inflammatory Breast Cancer
    Dr. Wulf is
    Distinguished
    . Learn about Inflammatory Breast Cancer.
    See more Inflammatory Breast Cancer experts
  • Paget Disease of the Breast
    Dr. Wulf is
    Distinguished
    . Learn about Paget Disease of the Breast.
    See more Paget Disease of the Breast experts
  • Triple-Negative Breast Cancer
    Dr. Wulf is
    Distinguished
    . Learn about Triple-Negative Breast Cancer.
    See more Triple-Negative Breast Cancer experts
  • Advanced
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Wulf is
    Advanced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • BRCA Positive Breast Cancer
    Dr. Wulf is
    Advanced
    . Learn about BRCA Positive Breast Cancer.
    See more BRCA Positive Breast Cancer experts
  • HER2 Negative Breast Cancer
    Dr. Wulf is
    Advanced
    . Learn about HER2 Negative Breast Cancer.
    See more HER2 Negative Breast Cancer experts
  • Pleuropulmonary Blastoma
    Dr. Wulf is
    Advanced
    . Learn about Pleuropulmonary Blastoma.
    See more Pleuropulmonary Blastoma experts
  • Small Cell Lung Cancer (SCLC)
    Dr. Wulf is
    Advanced
    . Learn about Small Cell Lung Cancer (SCLC).
    See more Small Cell Lung Cancer (SCLC) experts
  • Squamous Cell Lung Carcinoma
    Dr. Wulf is
    Advanced
    . Learn about Squamous Cell Lung Carcinoma.
    See more Squamous Cell Lung Carcinoma experts
  • Experienced
  • Cervical Cancer
    Dr. Wulf is
    Experienced
    . Learn about Cervical Cancer.
    See more Cervical Cancer experts
  • EGFR Positive Lung Cancer
    Dr. Wulf is
    Experienced
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Familial Colorectal Cancer
    Dr. Wulf is
    Experienced
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Hormone Replacement Therapy (HRT)
    Dr. Wulf is
    Experienced
    . Learn about Hormone Replacement Therapy (HRT).
    See more Hormone Replacement Therapy (HRT) experts
  • Large-Cell Lung Carcinoma
    Dr. Wulf is
    Experienced
    . Learn about Large-Cell Lung Carcinoma.
    See more Large-Cell Lung Carcinoma experts
  • Lung Adenocarcinoma
    Dr. Wulf is
    Experienced
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    Once you submit your request, MediFind will reach out to the provider’s office to help schedule your appointment. Note that this is not a confirmed booking. You’ll receive a status update via email within 1–2 business days.

    Patient Details

    This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.